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Abstract
The management of rheumatoid arthritis has changed dramatically over the last
three decades. Improvements in clinical assessment have been a key driver of
these changes. However, in the last five years, three areas of unresolved
uncertainty have dominated specialist thinking in the field. These challenges
comprise identifying the optimal management target, determining how best to
reach this target by using intensive treatments, and individualising
management because not all patients need or respond to identical treatments.
The key problem that links each of these areas is balancing different types of
evidence and is most readily appreciated in relation to treatment intensity.
Giving more intensive therapy improves outcomes but also increases risks and,
with biologic treatments, substantially increases drug costs. Specialists and
healthcare funders need to agree on how best to rationalise optimal care for
patients with what is most effective and safe and what is affordable.
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Introduction
Historical treatments for rheumatoid arthritis (RA) used thirty to 
forty years ago were limited and outcomes were poor. Persisting 
joint inflammation and increasing disability caused major health 
problems. These existing treatments also often led to significant 
toxicities. As a consequence, patients’ quality of life was reduced 
and their lives were often shortened.
Two inter-related developments changed this historic scenario. 
The end results were greatly improved clinical outcomes. The first 
improvement was identifying new drugs and new treatment strate-
gies. The second change was developing new and better ways to 
assess RA and define the benefits of treatment. Whilst therapeutic 
innovations are widely recognised, the importance of assessments 
has received less emphasis. However, without better assessment 
methods, the ability to identify new drugs would have been greatly 
reduced.
Historical changes in assessments
Before 1990, there were multiple ways to assess RA. Approaches 
included recording the duration of morning stiffness, measuring 
finger sizes using jewellers’ rings, and recording grip strength using 
modified sphygmomanometers. There was no sensitive or agreed 
way to assess the impact of RA on erosive joint damage, physical 
function, or quality of life. Finally, recording adverse events was 
difficult, and the toxicities of many early drugs including steroids 
were not fully understood when these treatments were introduced.
The situation changed substantially with the development of an 
internationally agreed core data set to assess disease activity1. This 
change was linked to the introduction of summary measures of 
response such as the disease activity score for 28 joints (DAS28)2 
and the American College of Rheumatology (ACR) response 
criteria3. There were also substantial advances in assessing disability 
using summary measures such as the health assessment ques-
tionnaire (HAQ). Assessing structural changes in joints by 
making better use of conventional X-rays and adopting new 
imaging modalities such as ultrasound and magnetic resonance 
imaging has also been important. Finally, understanding the 
complexities of drug toxicities led to the establishment of large 
national registries. They provided long-term real-world information 
about the potential toxicities of existing and new drugs.
Historical changes in drug treatments
Until the 1980s, the treatment of RA involved treating symptoms 
with analgesics and non-steroidal anti-inflammatory drugs, giv-
ing non-responders disease-modifying drugs that were either toxic 
(such as gold) or relatively ineffective (such as hydroxychloro-
quine), and using steroids as needed to control inflammation, 
knowing that their toxicity would risk long-term problems.
Since then, three main developments have occurred. Firstly, 
more effective and less toxic disease-modifying drugs including 
methotrexate, sulfasalazine, and leflunomide became available4. 
Secondly, starting with tumour necrosis factor (TNF) inhibitors, a 
range of both highly effective and relatively safe biologic agents 
was developed5. Finally, in recent years, new orally effective kinase 
inhibitors, particularly JAK inhibitors, have been developed6.
Improved assessment methods facilitated these developments. 
Summary responses such as DAS28 and ACR responders reduced 
the sample sizes needed in trials and provided comparative data 
across different treatments. Assessing the progression of erosive 
damage showed treatments were genuinely disease modifying. 
Measuring disability and quality of life enabled the development 
of cost-effectiveness methods, which is important to help justify the 
use of high-cost biologics. Finally, understanding the risks of drug 
toxicity was vital in enabling new treatments to be used without 
undue concern.
Recent challenges
This historical background has led to three current challenges in 
the management of inflammatory arthritis. All of them reflect the 
way in which clinical assessments and drug treatments developed 
over the last three decades. Each of them remains unresolved. These 
challenges relate to identifying the optimal treatment target, deter-
mining how best to reach this target by using intensive treatments, 
and the need to individualise management because not all patients 
need or respond to identical treatments.
Present uncertainties
There are three main uncertainties about the future best 
management of RA. These comprise the optimal management 
target, the most suitable intensive treatment strategies, and the role 
of bespoke care.
Management targets
Patients want their illnesses to be cured. In long-term diseases 
like RA, in which a cure seems unachievable, they would like the 
equally acceptable alternative of disease remission. When patients 
with arthritis achieve remission, they have less disability and a 
better quality of life. As a consequence, remission seems a highly 
appropriate treatment target. A whole treatment movement has 
grown out of this approach – “Treat To Target” – in which treatment 
is increased until patients achieve the defined target7. The growing 
focus on early treatment of inflammatory arthritis has been associ-
ated with an increased emphasis by patients on being able to return 
to normality as soon as possible8.
One central research issue, which remains open to debate, is what 
the target should be. Remission appears to be the most rational 
target. However, there are multiple ways of defining remission, 
and it is uncertain which definition is optimal in clinical practice. 
An associated theme is whether it is preferable to aim for patients 
achieving deep and sustained remissions or whether it is better 
to have modest levels of remission for short periods of time, or 
even to have sustained low-disease-activity levels.
There are trade-offs between achieving optimal remissions and 
maximising the numbers of patients who are able to reach the ther-
apeutic target. The deeper and more sustained the remission, the 
fewer patients likely to be able to reach it. In contrast, achieving 
low-disease-activity levels is less beneficial for individual patients 
but substantially more patients can achieve this target.
The remission criterion most widely used as a treatment target is 
DAS28 remission9. With modern treatments, particularly in patients 
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with early RA, up to 50% of patients can achieve DAS28 remis-
sion. A substantial theoretical limitation of DAS28 remissions is 
the major impact of erythrocyte sedimentation rate (ESR) levels on 
achieving it. At low levels of DAS28, the ESR contributes 70% or 
more of the score. This means that the chance of obtaining a DAS28 
remission is particularly dependent on controlling the ESR.
Alternative remission criteria, such as remission using the simple 
disease activity index (SDAI), appear more rational10. This meas-
ure is easier to calculate and is not subject to the impact of the 
ESR in determining remission status. SDAI combines joint counts, 
global assessments, and C-reactive protein levels rather than the 
ESR. SDAI remissions are supported by international collabora-
tive groups, which consider it preferable to DAS28 remissions. 
Currently, SDAI is less often used in routine practice than DAS28. 
Whether this will change over time is uncertain.
An interesting variant on the approach to assess the severity of syn-
ovitis is the clinical disease activity index (CDAI), which combines 
joint counts with global assessments and has no laboratory assess-
ment of inflammation10. CDAI remissions may be particularly 
useful in assessing the efficacy of treatments that have less impact 
on laboratory measures of inflammation. There are other definitions 
of remission, including the more robust but difficult-to-achieve 
Boolean remission11, which is rarely adopted in clinical practice.
Sustained remission and drug-free remission are two additional 
facets of remission. There are no widely agreed criteria for how 
long sustained remission should last, but some experts have sug-
gested that 6 months appears to be reasonable. The longer remis-
sion lasts, and particularly if patients have been able to stop 
anti-rheumatic drug treatment, the better the outcome for patients.
One limitation of targeting remission is that it places controlling the 
features of joint inflammation over and above other assessments, 
such as disability and joint damage. The other limitation is that it 
avoids targeting other outcomes that may be more important for 
patients. For example, targeting other symptoms such as pain and 
fatigue, which are of consequence to patients, may be equally ben-
eficial. Finally, remission may be the best target in early disease, 
but in established RA, when there may already be some irrevers-
ible damage to joints, it may be less relevant and its benefits less 
obvious.
Intensive treatment strategies
There are two ways to deliver intensive treatment in RA. Firstly, 
two or more conventional disease-modifying drugs can be used 
concurrently, with or without glucocorticoids. Secondly, biologics 
can be combined with methotrexate or another disease-modifying 
drug. There is evidence that both of these approaches are effective 
in reducing synovitis, limiting erosive damage, and improving qual-
ity of life.
Combining conventional disease-modifying drugs has one major 
drawback: it increases toxicity. Many of the earlier combinations, 
particularly those involving injectable gold, had too much toxic-
ity to make them useful in clinical practice. Triple therapy using 
methotrexate, sulfasalazine, and hydroxychloroquine is considered 
to have the best efficacy and the least toxicity12. It has become 
the most widely used conventional combination. The efficacy of 
disease-modifying drug combinations can be enhanced by short-
term treatment with steroids, including intramuscular injections of 
methylprednisolone.
Early biologics, particularly TNF inhibitors such as inflixi-
mab, were given in combination with methotrexate because this 
approach improved sustained efficacy. Most biologics are now 
combined with methotrexate. There is evidence that some biolog-
ics, particularly the interleukin-6 inhibitor tocilizumab, might also 
be effective in monotherapy when methotrexate is contraindicated. 
There is limited evidence that other disease-modifying drugs are 
beneficial when used with biologics. However, when TNF inhibi-
tors are combined with triple therapy (methotrexate, sulfasalazine, 
and hydroxychloroquine), more patients remain on their biological 
treatment13.
Strategy trials show that intensive combinations using combina-
tions of conventional disease-modifying drugs have broadly simi-
lar efficacy to combination using biologic agents, particularly TNF 
inhibitors with methotrexate. The relative benefits of combining 
methotrexate with other disease-modifying drugs or with high-dose, 
short-term glucocorticoids in early disease are contentious, and dif-
ferent trials provide varying perspectives14,15. The main benefit of 
combinations of conventional disease-modifying drugs is that they 
provide similar improvements in quality of life but cost substan-
tially less. As a consequence, they would invariably be preferred 
when viewed from a cost-effective perspective. However, biologic 
combinations are more rapidly effective and have less toxicity. 
The introduction of biosimilar biologics may change the balance 
of health economic benefit. Some recent trials comparing different 
strategies are summarised in Table 116–20.
The various strategy trials have so far failed to resolve a number 
of critical uncertainties about treatment intensity. In established 
RA, when patients have failed to respond to at least one conven-
tional disease-modifying drug, such as methotrexate, there is some 
doubt about whether it is best to try a combination of conventional 
disease-modifying drugs or to start biological treatments. From the 
perspective of healthcare funders, there is much to be said about 
starting combinations of conventional drugs followed by biologics 
in patients who fail to respond. In these patients, the slower onset 
of action of conventional drugs is of limited consequence. As the 
use of combinations of conventional drugs increases, this issue 
becomes less crucial, as most patients with severe disease will have 
already received this lower cost form of intensive therapy.
The main area in which there is debate concerns the initial treat-
ment of RA. Many experts believe that patients with early RA 
need to be treated with methotrexate monotherapy before receiving 
other treatments. This perspective is part of existing guidance in 
North America and much of Europe21,22. Other guidance, notably 
from the National Institute for Health and Clinical Excellence in 
England, recommends starting combinations of conventional 
disease-modifying drugs in all patients with early disease when 
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first seen by specialists23. In addition, there is considerable 
evidence from clinical trials that patients with early RA benefit 
substantially from early intensive treatment with biologics24.
The rationale for starting patients on methotrexate monotherapy is 
that many patients respond well to this treatment and that using it 
initially reduces the risks of adverse events and is less expensive. 
The argument in favour of starting with initial intensive management 
strategies is that there is an extensive evidence base from clinical 
trials that this approach is more effective and gives less long-term 
erosive progression. Given the perspective that patients with early 
RA need rapid intervention with effective treatments, it seems illog-
ical to start with combinations of conventional disease-modifying 
drugs when biologics act so much more rapidly. Nevertheless, the 
expense of biologics probably means they will not be universally 
used for some time yet. In the fullness of time, it seems inevitable 
that their use as a first treatment in early RA will gradually increase, 
though both health economic factors and concerns about risks such 
as more infections will limit the extent of any changes.
Bespoke management
RA is a variable disease. In some patients it is mild, and in others 
it is severe. Not all patients need identical treatment. It therefore 
seems self-evident that we should move on from standard care, 
aimed at all patients, towards individualised care: in other words, 
from “one size fits all” into the realm of bespoke care25. There are 
several examples of known factors that predict the need for more 
intensive management. Firstly, almost all drug trials enrol patients 
with active RA who have high DAS28 scores and many tender and 
swollen joints. The exact dividing line between active and inac-
tive RA is not well defined. However, it usually involves patients 
having at least three swollen and tender joints and some evidence 
of an elevated ESR or C-reactive protein level. Patients with 
inactive disease do not usually have their treatment changed unless 
they have adverse events with one drug and need an alternative 
agent.
There is some evidence that patients who are seropositive for anti-
citrullinated protein antibody (ACPA) are more likely to benefit 
from intensive treatment. Secondary analysis of early RA trial data 
has shown that intensive treatment is only beneficial in ACPA- 
positive patients26. The impact of ACPA status on remissions with 
intensive treatment is shown in Figure 1. It is likely that other mark-
ers of severe disease also help identify those patients most likely 
to benefit from higher treatment intensities. However, there is also 
evidence that low-risk early arthritis patients benefit from bridging 
therapy with glucocorticoids given together with methotrexate27. 
This more recent research implies current assessments of prognos-
tic risk are incomplete, and for the present every patient with early 
RA could benefit from some form of initial intensive treatment.
There is more evidence about prognostic biomarkers for erosive 
progression in RA. Patients at higher risk of subsequent erosive 
disease can be prospectively identified using matrices of dif-
ferent biomarkers and clinical measures28,29. It is likely that the 
identification of these higher risk patients using immunological 
and other markers will help guide treatment decisions in the years 
ahead.
Some lifestyle factors have also been implicated. Smoking status is 
the best known of these factors. Observational study data have sug-
gested that smokers are less likely to respond to treatments such as 
biologics30, which is also shown in Figure 1. However, the informa-
tion about the negative effects of smoking is not fully evaluated. So 
far, there have been no suggestions that smokers should be treated 
differently from non-smokers.
Table 1. Trials comparing intensive treatment strategies using conventional and biologic drugs.
Trial Year Type Patients Endpoint Combination Therapy Primary Outcome Comparison 
of Groups
Conventional Biologic 




DMARDs/infliximab Change in HAQ and X-ray score Similar
Tear17 2012 Early RA 755 2 years Triple therapy Methotrexate/etanercept DAS28 from 12–24 months Similar
Swefot18 2012 Methotrexate Failure 258 2 years Triple therapy Methotrexate/infliximab Change DAS28 Similar
RACAT19 2013 Methotrexate Failure 353 1 year Triple therapy Methotrexate/etanercept Change DAS28 Similar
TACIT20 2015 Established RA 205 1 year Any DMARDs DMARD/TNF inhibitor Change HAQ Non-inferior
BeST and Tear trials had four groups, but only comparison of combination DMARDs and DMARD/biologics has been reported in this table.
Triple therapy: methotrexate, sulfasalazine, and hydroxychloroquine.
Abbreviations: DAS28, disease activity score for 28 joints; DMARDs, disease-modifying anti-rheumatic drugs; HAQ, health assessment questionnaire;  
RA, rheumatoid arthritis; TNF, tumour necrosis factor.
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It seems inevitable that in the fullness of time a range of pre-
dictive factors for drug treatment will be known. At present, 
there is insufficient information to know how much benefit this 
will bring to disease management. It is without doubt an area of 
intense research interest but so far it remains outside routine 
practice.
Impact on new treatments
We are moving beyond the present biologics era with the devel-
opment of new orally acting drugs. Kinase inhibitors are likely to 
become an important new class of drugs. Although they have been 
evaluated using the historic approach of assessing with the conven-
tional core data set measures, there are moves to provide informa-
tion about their ability to induce remissions.Extending the evidence 
base in this way is an encouraging innovation.
Future developments
Despite the impossibility of predicting the future, it remains 
tempting to suggest how research will develop. At present, it seems 
inevitable that the current focus on early intensive treatment for 
RA will continue and, if anything, increase.
The main focus of this development is likely to be further efforts 
to induce remission in early disease by optimising the initial 
treatments used. One way to achieve this goal is to start with 
high-intensity treatment and follow this with lower-intensity 
maintenance therapy. I believe this is a likely development from 
the current use of combinations of conventional and biological 
drugs. There is evidence that this approach is increasing remissions 
and reducing active disease in routine practice. Evidence support-
ing this view from my own unit is shown in Figure 231.
Figure 1. Potential markers of individualised responses. (a) Impact of anti-citrullinated protein antibody (ACPA) status on remissions in 
early rheumatoid arthritis trial26 showing benefit of intensive treatment restricted to ACPA-positive patients. (b) Impact of smoking status with 
ACPA positivity during rituximab therapy showing only non-smokers had major benefit30.
Figure 2. Temporal changes in treatment intensity, remission, and active disease from South London specialist centres showing 
increase in remissions as treatment intensity increases in routine practice31. Abbreviations: DMARD, disease-modifying anti-rheumatic 
drug.
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Another focus is identifying patients with RA as soon as possible 
and even screening for “pre-rheumatoid” patients who are positive 
for ACPA but currently do not have definite RA. There is some evi-
dence that treating these patients with disease-modifying drugs or 
steroids can prevent the onset of RA. There are currently major dif-
ficulties in identifying and classifying them. However, this focus 
on earlier and earlier disease is changing perspectives. There is 
also some evidence, albeit incomplete, that they are also improving 
outcomes.
Over the four decades I have been involved in treating RA, there 
have been major changes in its management and substantially 
better outcomes have been achieved. The pace of change contin-
ues and, as a consequence, to my mind, RA appears to be a far 
less onerous burden for patients. However, from the perspective 
of individual patients, this benefit is less obvious because the 
impact of a moderate disease upon everyday lives is not much 
less than the impact of a severe disease. This apparent paradox 
means that there is still a long way to go in improving the lives of 
people with arthritis.
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